DCE-MRI-based radiomics in predicting angiopoietin-2 expression in hepatocellular carcinoma

Sung H, Ferlay J, Siegel R ,Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin, 2021, 71(3): 209-249.

Article  PubMed  Google Scholar 

Lefere S, Van de Velde F, Hoorens A, Raevens S, Campenhout S, Vandierendonck A, Neyt S, Vandeghinste B, Vanhove C, Debbaut C, et al. Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease. Hepatology, 2019, 69(3): 1087-1104.

Article  CAS  PubMed  Google Scholar 

Carmeliet P, Jain R K. Molecular mechanisms and clinical applications of angiogenesis. Nature, 2011, 473(7347): 298-307.

Article  CAS  PubMed  Google Scholar 

Liu N, Liu M, Fu S, Wang J, Tang H, Isah A, Chen D, Wang X. Ang2-Targeted Combination Therapy for Cancer Treatment. Front Immunol, 2022,13:949553.

Article  CAS  PubMed  Google Scholar 

Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer, 2010, 10(8): 575-585.

Article  CAS  PubMed  Google Scholar 

Tahara M, Schlumberger M, Elisei R, Habra M, Kiyota N, Paschke R, Dutcus C, Hihara T, McGrath S, Matijevic M, et al. Exploratory analysis of biomarkers associated with clinical outcomes from the study of lenvatinib in differentiated cancer of the thyroid. Eur J Cancer, 2017, 75: 213-221.

Article  CAS  PubMed  Google Scholar 

Schlumberger M, Jarzab B, Cabanillas M, Robinson B, Pacini F, Ball D, McCaffrey J, Newbold K, Allison R, Martins R, et al. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer. Clin Cancer Res, 2016, 22(1): 44-53.

Article  CAS  PubMed  Google Scholar 

Chuma M, Uojima H, Numata K, Hidaka H, Toyoda H, Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, et al. Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma. Cancers (Basel), 2020, 12(2).

Article  CAS  PubMed  Google Scholar 

Rutman A, Kuo M. Radiogenomics: creating a link between molecular diagnostics and diagnostic imaging. Eur J Radiol, 2009, 70(2): 232-241.

Article  PubMed  Google Scholar 

Le Bihan D, Breton E, Lallemand D, Grenier P, Cabanis E, Laval-Jeantet M. MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology, 1986, 161(2): 401-407.

Article  PubMed  Google Scholar 

Dixon W. Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging: a modest proposal with tremendous potential. Radiology, 1988, 168(2): 566-567.

Article  CAS  PubMed  Google Scholar 

Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, Stiphout R, Granton P, Zegers C, Gillies R, Boellard R, Dekker A, et al. Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer, 2012, 48(4): 441-446.

Article  PubMed  Google Scholar 

Tao Y, Shi Y, Gong X, Li L, Li Z, Yang L, Zhang X. Radiomic Analysis Based on Magnetic Resonance Imaging for Predicting PD-L2 Expression in Hepatocellular Carcinoma. Cancers (Basel), 2023,15(2).

Article  CAS  PubMed  Google Scholar 

Chen Z, Shen S, Ding Y, Wang W, Tao J, Liang L, Hu W, The angiogenic and prognostic implications of VEGF, Ang-1, Ang-2, and MMP-9 for hepatocellular carcinoma with background of hepatitis B virus. Med Oncol, 2009, 26(3): 365-371.

Article  CAS  PubMed  Google Scholar 

Stroom J, Blaauwgeers H, van Baardwijk A, Boersma L, Lebesque J, Theuws J, van Suylen B, Klomp H, Liesker K, van Pel R, et al. Feasibility of pathology-correlated lung imaging for accurate target definition of lung tumors. Int J Radiat Oncol Biol Phys, 2007, 69(1): 267-275.

Article  PubMed  Google Scholar 

Kickingereder P, Burth S, Wick A, Götz M, Eidel O, Schlemmer H, Maier-Hein K, Wick W, Bendszus M, Radbruch A, et al. Radiomic Profiling of Glioblastoma: Identifying an Imaging Predictor of Patient Survival with Improved Performance over Established Clinical and Radiologic Risk Models. Radiology, 2016, 280(3): 880-889.

Article  PubMed  Google Scholar 

Orlandi P, Solini A, Banchi M, Brunetto M, Cioni D, Ghiadoni L, Bocci G. Antiangiogenic Drugs in NASH: Evidence of a Possible New Therapeutic Approach. Pharmaceuticals (Basel), 2021, 14(10).

Article  CAS  PubMed  Google Scholar 

Parmar D, Apte M. Angiopoietin inhibitors: A review on targeting tumor angiogenesis. Eur J Pharmacol, 2021, 899: 174021.

Article  CAS  PubMed  Google Scholar 

Dong X, Zhong J, Liu T, Chen Y, Tang Y, Yang J. Angiopoietin-2 regulates vessels encapsulated by tumor clusters positive hepatocellular carcinoma nest-type metastasis via integrin α5β1]. Zhonghua Yi Xue Za Zhi, 2021, 101(9): 654-660.

CAS  PubMed  Google Scholar 

Choi G, Jang E, Kim J, Jeong S. Prognostic role of plasma level of angiopoietin-1, angiopoietin-2, and vascular endothelial growth factor in hepatocellular carcinoma. World J Gastroenterol, 2021, 27(27): 4453-4467.

Article  CAS  PubMed  Google Scholar 

Lee H, Rha S, Chung Y, Shim H, Kim Y, Hur J, Hong Y, Choi B. Tumor perfusion-related parameter of diffusion-weighted magnetic resonance imaging: correlation with histological microvessel density. Magn Reson Med, 2014, 71(4): 1554-1558.

Article  PubMed  Google Scholar 

Wada H, Nagano H, Yamamoto H, Yang Y, Kondo M, Ota H, Nakamura M, Yoshioka S, Kato H, Damdinsuren B, et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int, 2006, 26(4): 414-423.

Article  CAS  PubMed  Google Scholar 

Zheng J, Gong X, Tao Y, Wang R, Yang G, Li J, Ren T, Li Z, Yang C, Wang W, et al. A Correlative Study Between IVIM-DWI Parameters and the Expression Levels of Ang-2 and TKT in Hepatocellular Carcinoma. Front Oncol, 2020,10:594366.

Article  PubMed  Google Scholar 

Vietti V, Lewis S, Hectors S, Said D, Taouli B, Hoshida Y. Radiological Diagnosis and Characterization of HCC.2019: 71-92.

Pinker K, Shitano F, Sala E, Do R, Young R, Wibmer A, Hricak H, Sutton E, Morris E. Background, current role, and potential applications of radiogenomics. J Magn Reson Imaging, 2018, 47(3): 604-620.

Article  PubMed  Google Scholar 

Giannini E, Bucci L, Garuti F, Brunacci M, Lenzi B, Valente M, Caturelli E, Cabibbo G, Piscaglia F, Virdone R, et al. Patients with advanced hepatocellular carcinoma need a personalized management: A lesson from clinical practice. Hepatology, 2018, 67(5): 1784-1796.

Article  CAS  PubMed  Google Scholar 

Sartoris R, Gregory J, Dioguardi B, Ronot M, Vilgrain V. HCC advances in diagnosis and prognosis: Digital and Imaging. Liver Int, 2021, 41 Suppl 1: 73-77.

Article  PubMed  Google Scholar 

Hectors S, Lewis S, Besa C, King M, Said D, Putra J, Ward S, Higashi T, Thung S, Yao S, et al. MRI radiomics features predict immuno-oncological characteristics of hepatocellular carcinoma. Eur Radiol, 2020, 30(7): 3759-3769.

Article  PubMed  Google Scholar 

Jia H, Jiang X, Zhang K, Shang J, Zhang Y, Fang X, Gao F, Li N, Dong J. A Nomogram of Combining IVIM-DWI and MRI Radiomics From the Primary Lesion of Rectal Adenocarcinoma to Assess Nonenlarged Lymph Node Metastasis Preoperatively. J Magn Reson Imaging, 2022, 56(3): 658-667.

Article  PubMed  Google Scholar 

Zhang Y, Liu L, Zhang K, Su R, Jia H, Qian L, Dong J. Nomograms Combining Clinical and Imaging Parameters to Predict Recurrence and Disease-free Survival After Concurrent Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer. Acad Radiol, 2022, 30(3):499-508.

Article  PubMed  Google Scholar 

留言 (0)

沒有登入
gif